Intravitreal aflibercept injection for exudative age-related macular degeneratio
Not Applicable
- Conditions
- Age-Related Macular Degeneration
- Registration Number
- JPRN-UMIN000010997
- Lead Sponsor
- Department of Ophthalmology, Fukushima Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)The greatest linear dimension (GLD)>12 Macular Photocoagulation Study Disc Areas 2)Presence of subretinal hemorrhage, scar or macular fibrosis(>50% lesion area) 3)Prior treatment with anti-VEGF drugs, photodynamic therapy 4)Prior treatment with dexamethasone(within 6 months) or triamcinolone (within 30 days), intraocular surgery(within 3 months 5)Active intraocular inflammation 6)Hypersensitivity or allergy to fluoresceinor or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products 7)Patients who the doctor in charge judges are ineligible for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of maintained visual acuity at month 12
- Secondary Outcome Measures
Name Time Method Change of best-corrected visual acuity (BCVA) and central retinal thickness. Proportion of subretinal fluid and regression ofpolypoidal lesion.